1. Home
  2. BLRX vs RGS Comparison

BLRX vs RGS Comparison

Compare BLRX & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • RGS
  • Stock Information
  • Founded
  • BLRX 2003
  • RGS 1922
  • Country
  • BLRX Israel
  • RGS United States
  • Employees
  • BLRX N/A
  • RGS N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • RGS Other Consumer Services
  • Sector
  • BLRX Health Care
  • RGS Consumer Discretionary
  • Exchange
  • BLRX Nasdaq
  • RGS Nasdaq
  • Market Cap
  • BLRX 36.0M
  • RGS 53.6M
  • IPO Year
  • BLRX 2011
  • RGS 1991
  • Fundamental
  • Price
  • BLRX $0.20
  • RGS $25.31
  • Analyst Decision
  • BLRX Strong Buy
  • RGS
  • Analyst Count
  • BLRX 2
  • RGS 0
  • Target Price
  • BLRX $5.50
  • RGS N/A
  • AVG Volume (30 Days)
  • BLRX 1.7M
  • RGS 39.7K
  • Earning Date
  • BLRX 11-25-2024
  • RGS 01-29-2025
  • Dividend Yield
  • BLRX N/A
  • RGS N/A
  • EPS Growth
  • BLRX N/A
  • RGS N/A
  • EPS
  • BLRX N/A
  • RGS 37.55
  • Revenue
  • BLRX $21,991,000.00
  • RGS $195,670,000.00
  • Revenue This Year
  • BLRX N/A
  • RGS N/A
  • Revenue Next Year
  • BLRX N/A
  • RGS N/A
  • P/E Ratio
  • BLRX N/A
  • RGS $0.70
  • Revenue Growth
  • BLRX N/A
  • RGS N/A
  • 52 Week Low
  • BLRX $0.19
  • RGS $3.87
  • 52 Week High
  • BLRX $1.68
  • RGS $35.50
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 25.94
  • RGS 58.86
  • Support Level
  • BLRX $0.23
  • RGS $21.49
  • Resistance Level
  • BLRX $0.56
  • RGS $24.35
  • Average True Range (ATR)
  • BLRX 0.03
  • RGS 1.86
  • MACD
  • BLRX 0.00
  • RGS 0.07
  • Stochastic Oscillator
  • BLRX 11.82
  • RGS 89.67

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About RGS Regis Corporation

Regis Corp owns, franchises, and operates beauty salons throughout North America and the United Kingdom. The company's locations provide salon products and services to the mass market, including haircutting, styling, and hair coloring. The vast majority of Regis' salons are in strip malls, shopping centers, and Wal-Mart stores in North America and serve price-conscious customers. The company derives the majority of its revenue from these locations. The sale of products also contributes a relatively significant percentage of total sales. Regis also operates a smaller portfolio of premium salons across North America and the U.K. The company's majority brands include SmartStyle, Cost Cutters, and Supercuts.

Share on Social Networks: